| Mrs Virginia Ann Baker, MSN APN | |
|
5758 S Maryland Ave # Mc9024, Chicago, IL 60637-1426 | |
| (773) 702-4108 | |
| Not Available |
| Full Name | Mrs Virginia Ann Baker |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 41 Years |
| Location | 5758 S Maryland Ave # Mc9024, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639547417 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 209.010056 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The University Of Chicago Medical Center | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The University Of Chicago Medical Center | 7618880766 | 754 |
News Archive
Results from a clinical trial demonstrate that high doses of an experimental H5N1 avian influenza vaccine can induce immune responses in healthy adults.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
On Monday, House Ways and Means Committee Chairman Charles Rangel, D- N.Y., told reporters that the House bill will include a new public insurance plan, Reuters/The Boston Globe reports.
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
› Verified 6 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
Results from a clinical trial demonstrate that high doses of an experimental H5N1 avian influenza vaccine can induce immune responses in healthy adults.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
On Monday, House Ways and Means Committee Chairman Charles Rangel, D- N.Y., told reporters that the House bill will include a new public insurance plan, Reuters/The Boston Globe reports.
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
› Verified 6 days ago
| Entity Name | The University Of Chicago Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031113000198 |
News Archive
Results from a clinical trial demonstrate that high doses of an experimental H5N1 avian influenza vaccine can induce immune responses in healthy adults.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
On Monday, House Ways and Means Committee Chairman Charles Rangel, D- N.Y., told reporters that the House bill will include a new public insurance plan, Reuters/The Boston Globe reports.
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Virginia Ann Baker, MSN APN 10933 Pioneer Trl, Frankfort, IL 60423-7971 Ph: (815) 690-5399 | Mrs Virginia Ann Baker, MSN APN 5758 S Maryland Ave # Mc9024, Chicago, IL 60637-1426 Ph: (773) 702-4108 |
News Archive
Results from a clinical trial demonstrate that high doses of an experimental H5N1 avian influenza vaccine can induce immune responses in healthy adults.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
On Monday, House Ways and Means Committee Chairman Charles Rangel, D- N.Y., told reporters that the House bill will include a new public insurance plan, Reuters/The Boston Globe reports.
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
› Verified 6 days ago
Heather Keldahl, CRNA Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1653 W Congress Pkwy, Jelke 739, Chicago, IL 60612 Phone: 312-942-6504 Fax: 312-942-5773 | |
Nancy Therese Scott, DNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 5841 S Maryland Avenue, University Of Chicago Medicine, Chicago, IL 60637 Phone: 773-926-9147 Fax: 773-702-8690 | |
Patricia Nwadinma Ezirike, PMHNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 2207 W Lunt Ave, Chicago, IL 60645 Phone: 773-297-7911 | |
Gabriel Campos, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 773-702-1927 Fax: 773-702-2837 | |
Maria Barnes, C.N.S. Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 773-702-1000 | |
Mary Jane Welch, NP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 2150 W Harrison St, Chicago, IL 60612 Phone: 312-942-3112 Fax: 312-942-2874 | |
Nancy Ruth Meyer, APN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 2545 S King Dr, Chicago, IL 60616 Phone: 312-842-7117 |